Exact Sciences to Merge with Genomic Health Forming a New Cancer Diagnostics Company

 Exact Sciences to Merge with Genomic Health Forming a New Cancer Diagnostics Company

Exact Sciences to Merge with Genomic Health Forming a New Cancer Diagnostics Company

Shots:

  • Exact Sciences enter into a merger agreement with Genomic in cash & stock transaction for $72/share making the total deal value $2.8B. Genomic to receive $27.50 in cash & $44.50 in shares of Exact Sciences stock for each owned share based on the closing price value as of Jul 26, 2019. The transaction is expected to be completed in H2’19
  • Exact Sciences is expected to own ~91% share of the combined company while remaining will be owned by Genomic. The newly formed company will offer Exact Sciences’ Cologuard and Genomic Health’s Oncotype DX, commercially available in 90+ countries with its expected revenue ~$1.6B in 2020
  • Cologuard is a non-invasive colon cancer screening test utilizes stool DNA technology to diagnose colon cancer & precancer patients. Oncotype IQ platform is a genomic-based diagnostic test which has guided personalized treatment decisions for cancer patients across the globe

Click here to­ read full press release/ article | Ref: Exact Sciences | Image: Genomic Health

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post